SCHEDULE: BroadOak Funds Secure Significant Stake in Harvard Bioscience

BroadOak Income Fund and affiliates have provided Harvard Bioscience with a $45 million loan facility, gaining substantial equity interest and a board seat.

Summary

• BroadOak Income Fund, L.P., BroadOak Fund VI, L.P., BroadOak Capital Partners, LLC, and William Snider collectively reported beneficial ownership of 846,000 shares of Harvard Bioscience Inc. common stock, representing 15.97% of the class.
• This ownership stems primarily from a $45 million Loan and Security Agreement entered into on December 17, 2025, between Harvard Bioscience and a syndicate of lenders including BroadOak Income Fund and BroadOak Fund VI.
• The loan facility comprises a $10.0 million Term A Loan, a $22.5 million Term B Loan, and a $7.5 million convertible Term C Loan, all maturing on December 17, 2029.
• The Term C Loan is convertible into common stock at $10.00 per share and can be converted at the lenders' option or automatically if the share price exceeds $15.00 for 30 consecutive trading days.
• In connection with the loan, Harvard Bioscience issued warrants to purchase 200,000 shares of common stock at an exercise price of $5.00 per share, with a seven-year term.
• William Snider, a partner at BroadOak Capital Partners, was appointed to Harvard Bioscience's board of directors and compensation committee, effective December 17, 2025.
• The proceeds from the Term Loans will be used to repay a prior credit facility, cover transaction fees, and for general corporate purposes.
• All share and price figures reflect a 10:1 reverse stock split effected by Harvard Bioscience on March 13, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a necessary but expensive financing for Harvard Bioscience, providing liquidity but at a high cost and with significant dilution potential and restrictive covenants, reflecting underlying financial challenges.

Positives

• Harvard Bioscience secured $45 million in financing, addressing its prior credit facility and providing working capital.
• The loan structure includes a convertible component (Term C Loan) and warrants, aligning lenders' interests with potential equity upside.
• The appointment of William Snider to the board provides BroadOak with direct oversight and influence, potentially enhancing strategic direction.
• The establishment of a Product, Operations and Scientific Advisory Board, with BroadOak's input, could improve operational efficiency and product strategy.

Negatives

• The loan carries a high interest rate, starting at 12.80% per annum, which could be a significant financial burden.
• Prepayment premiums (up to 3.00%) and a 10.00% exit fee (except for converted Term C loans) limit Harvard Bioscience's financial flexibility.
• The loan is secured by substantially all of Harvard Bioscience's assets and guaranteed by its domestic subsidiaries, increasing financial risk.
• Stringent financial covenants, including minimum liquidity and Adjusted EBITDA, could restrict operational and strategic maneuvers.
• Significant dilution potential exists from the conversion of the Term C Loan and exercise of warrants, as well as the existing beneficial ownership.

Risks

• High interest expense and potential prepayment penalties could strain Harvard Bioscience's cash flow.
• Failure to meet financial covenants (minimum liquidity, Adjusted EBITDA) could trigger an an event of default, leading to accelerated repayment or loss of assets.
• The conversion of the Term C Loan and exercise of warrants will dilute existing shareholders' equity.
• The company's ability to extend the maturity date by one year is contingent on achieving a specific adjusted EBITDA milestone, which may not be met.
• BroadOak, through its board representation and significant equity stake, may exert considerable influence over the company's strategic decisions, which may not always align with all shareholders' interests.

Future Outlook

The Reporting Persons may seek to increase or decrease their position in Harvard Bioscience, influence management and the board, and consider strategic actions such as business combinations, dispositions, or changes to capitalization and board structure. The Issuer aims to extend the loan maturity by one year if it achieves a certain adjusted EBITDA milestone and will establish a Product, Operations and Scientific Advisory Board by March 31, 2026.

Management Comments

• BroadOak Income Fund and BroadOak Fund VI serve as investment vehicles and, on occasion, take an active role in the management of portfolio companies to enhance shareholder value.
• BroadOak Capital Partners provides growth capital and advisory services to life sciences companies.
• William Snider, as a member of the board of directors of the Issuer, may have influence over the corporate activities of the Issuer.
• The Reporting Persons may from time to time review, reconsider and change their position and/or change their purpose and/or develop such plans and may seek to influence management of the Issuer or the board of directors of the Issuer with respect to the business and affairs of the Issuer.

Industry Context

StockSavvy.ai notes that this financing package, characterized by a high interest rate and significant equity components (convertible debt, warrants), is typical for growth-stage life sciences companies seeking capital outside traditional bank lending, especially those with specific operational or financial challenges. The involvement of BroadOak, a specialist in life sciences growth capital, suggests a strategic partnership aimed at operational improvement and value creation, rather than just passive investment. The board seat and advisory board provisions indicate a hands-on approach, common in private equity-backed ventures, now extended to a publicly traded entity.

Comparison to Industry Standards

• The 12.80% initial interest rate is significantly higher than typical senior secured debt for mature, stable companies, reflecting the higher risk profile often associated with smaller, growth-oriented life sciences firms. For example, larger biotech firms might secure debt at 5-8% depending on market conditions and credit ratings.
• The inclusion of warrants (200,000 shares at $5.00) and a convertible loan ($7.5 million at $10.00 conversion price) is a common feature in venture debt or growth capital for life sciences, where lenders seek equity upside to compensate for higher risk and lower fixed returns compared to traditional loans. This structure is similar to financing rounds seen in companies like smaller biopharmaceutical developers or medical device startups that may not yet be profitable.
• The 10% exit fee and prepayment premiums are also characteristic of more aggressive debt financing terms, often seen in distressed situations or for companies with limited alternative funding options, contrasting with the lower or absent fees in investment-grade corporate debt.
• The requirement for a board seat and an advisory board with lender representation is a strong governance control mechanism, more akin to private equity investment terms than standard public company debt, indicating BroadOak's intent for active involvement in Harvard Bioscience's strategic and operational decisions.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for significant dilution from convertible debt and warrants. The high cost of debt and restrictive covenants could impact future profitability and flexibility. BroadOak's increased influence may lead to strategic shifts.
• Creditors: The new senior secured term loans replace a prior credit facility, potentially altering the company's debt structure and priority of claims.
• Employees: The establishment of an advisory board focused on operations and product lines could lead to strategic shifts impacting roles and departments.
• Management: Increased oversight and influence from BroadOak, particularly through Mr. Snider's board seat and the advisory board, will likely impact management's autonomy and strategic direction.

Next Steps

• Harvard Bioscience will make quarterly principal amortization payments on Term A and Term B Loans starting December 31, 2027.
• The Issuer may extend the loan maturity date by one year if it achieves a certain adjusted EBITDA milestone.
• Harvard Bioscience will establish a Product, Operations and Scientific Advisory Board before March 31, 2026.
• The Reporting Persons may increase or decrease their position in the Issuer through market transactions or exercise of conversion/warrant rights.
• The Reporting Persons may seek to influence management or the board regarding business affairs, capitalization, ownership structure, board composition, or potential business combinations.

Key Dates

Recommendation

The financing provides Harvard Bioscience with necessary capital and repays an existing credit facility, which is a positive for liquidity. However, the terms are expensive, including a high interest rate, significant fees, and potential for substantial shareholder dilution from the convertible loan and warrants. While BroadOak's active involvement could bring strategic benefits, the restrictive covenants and asset-backed nature of the loan indicate a higher risk profile. Given the mixed implications of securing essential funding at a high cost and potential dilution, a 'hold' recommendation is appropriate as investors assess the company's ability to leverage this capital for growth while managing the associated financial burdens and BroadOak's influence.

Keywords

Harvard Bioscience, BroadOak Income Fund, Schedule 13D, SEC Filing, Convertible Loan, Warrants, Equity Stake, Board Appointment, Debt Financing, Life Sciences, Corporate Governance, Reverse Stock Split, Investment Vehicle